Literature DB >> 8138894

The importance of modeling interoccasion variability in population pharmacokinetic analyses.

M O Karlsson1, L B Sheiner.   

Abstract

Individual pharmacokinetic parameters may change randomly between study occasions. Analysis of simulated data with NONMEM shows that ignoring such interoccasion variability (IOV) may result in biased population parameter estimates. Particular parameters affected and the extent to which they are biased depend on study design and the magnitude of IOV and interindividual variability. Neglecting IOV also results in a high incidence of statistically significant spurious period effects. Perhaps most important, ignoring IOV can lead to a falsely optimistic impression of the potential value of therapeutic drug monitoring. A model incorporating IOV was developed and its performance in the presence and absence of IOV was evaluated. The IOV model performs well with respect to both model selection and population parameter estimation in all circumstances studied. Analysis of two real data examples using this model reveals significant IOV in all parameters for both drugs and supports the simulation findings for the case that IOV is ignored: predictable biases occur in parameter estimates and previously nonexistent period effects are found.

Mesh:

Year:  1993        PMID: 8138894     DOI: 10.1007/bf01113502

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  7 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  Application of the NONMEM method to evaluation of the bioavailability of drug products.

Authors:  N Kaniwa; N Aoyagi; H Ogata; M Ishii
Journal:  J Pharm Sci       Date:  1990-12       Impact factor: 3.534

4.  Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; H C Schoemaker; A F Cohen; D D Breimer
Journal:  J Clin Pharmacol       Date:  1992-04       Impact factor: 3.126

5.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

6.  Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Authors:  M O Karlsson; U Bredberg
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

7.  Application of NONMEM to routine bioavailability data.

Authors:  D A Graves; I Chang
Journal:  J Pharmacokinet Biopharm       Date:  1990-04
  7 in total
  198 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.

Authors:  R L Lalonde; D Ouellet; E K Kimanani; D Potvin; L M Vaughan; M R Hill
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

3.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

4.  Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Authors:  Chantal Csajka; Thierry Buclin; Karin Fattinger; Hans R Brunner; Jérôme Biollaz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

6.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

7.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

8.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

9.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Pharmacokinetics of bupivacaine enantiomers in sheep: influence of dosage regimen and study design.

Authors:  L E Mather; A J Rutten; J L Plummer
Journal:  J Pharmacokinet Biopharm       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.